Tags

Type your tag names separated by a space and hit enter

Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK.
BMJ Open. 2017 04 24; 7(4):e014777.BO

Abstract

OBJECTIVE

The aims of this study were (1) to characterise the type of patient prescribed MP-AzeFlu (Dymista, a novel formulation of azelastine hydrochloride, fluticasone propionate and excipients in a single spray) in real life in the UK and physicians' reasons for prescribing it and (2) to quantify the personal and societal burden of allergic rhinitis (AR) in the UK prior to MP-AzeFlu prescription.

DESIGN, SETTING AND PARTICIPANTS

This multicentre, non-interventional study enrolled patients (n=193) with moderate-to-severe AR and acute symptoms who were eligible to receive treatment with MP-AzeFlu according to its licensed indications. Information was gathered on patient demographics, AR history and symptom severity, symptomatology and AR treatments in the previous calendar year (prior to MP-AzeFlu prescription). Physicians also recorded the number of previous AR visits, specific reasons for these visits and their reason for prescribing MP-AzeFlu.

RESULTS

Most patients had seasonal AR either alone (10.4%) or in combination with perennial AR (35.2%), but many had AR of unknown origin (35.8%). Prior to MP-AzeFlu prescription, patients reported troublesome symptoms (78.2%) and sleep disturbance (64.8%), with congestion considered the most bothersome (54.4%) and ocular symptoms reported by 68.4% of patients. The most frequent reason for MP-AzeFlu prescription was that other therapies were not sufficient in the past (78.8%) or not sufficient to treat acute symptoms (16.1%). 79.3% of patients reported using ≥2 AR therapies in the past year. An average of 1.6 (SD 1.9) doctor visits due to AR were reported prior to MP-AzeFlu prescription.

CONCLUSIONS

In the UK, MP-AzeFlu was prescribed for individuals (≥12 years) with moderate/severe AR irrespective of (1) previous AR treatment (mono or multiple), (2) previous or likely treatment failure, (3) phenotype, (4) number of previous physician visits for AR and (5) for the relief of both acute symptoms and in anticipation of allergen exposure.

Authors+Show Affiliations

Royal National Throat, Nose and Ear Hospital, London, UK.University of Aberdeen, Aberdeen, Scotland. Observational and Pragmatic Research Institute Pte Ltd, Singapore, Singapore.Univeristy Hospital of Wales, Cardiff, UK.Queen Elizabeth Hospital, Birmingham, UK.Royal Hallamshire, Sheffield, UK.Northern General Hospital, Sheffield, UK.Royal Albert & Edward Hospital, Wigan, UK.

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28442578

Citation

Scadding, Glenis, et al. "Multicentre, Non-interventional Study to Assess the Profile of Patients With Uncontrolled Rhinitis Prescribed a Novel Formulation of Azelastine Hydrochloride and Fluticasone Propionate in a Single Spray in Routine Clinical Practice in the UK." BMJ Open, vol. 7, no. 4, 2017, pp. e014777.
Scadding G, Price D, El-Shanawany T, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open. 2017;7(4):e014777.
Scadding, G., Price, D., El-Shanawany, T., Ahmed, S., Ray, J., Sargur, R., & Kumar, N. (2017). Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open, 7(4), e014777. https://doi.org/10.1136/bmjopen-2016-014777
Scadding G, et al. Multicentre, Non-interventional Study to Assess the Profile of Patients With Uncontrolled Rhinitis Prescribed a Novel Formulation of Azelastine Hydrochloride and Fluticasone Propionate in a Single Spray in Routine Clinical Practice in the UK. BMJ Open. 2017 04 24;7(4):e014777. PubMed PMID: 28442578.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. AU - Scadding,Glenis, AU - Price,David, AU - El-Shanawany,Tariq, AU - Ahmed,Shahzada, AU - Ray,Jaydip, AU - Sargur,Ravishankar, AU - Kumar,Nirmal, Y1 - 2017/04/24/ PY - 2017/4/27/entrez PY - 2017/4/27/pubmed PY - 2018/1/30/medline KW - Dymista KW - UK KW - allergic rhinitis KW - azelastine KW - fluticasone propionate SP - e014777 EP - e014777 JF - BMJ open JO - BMJ Open VL - 7 IS - 4 N2 - OBJECTIVE: The aims of this study were (1) to characterise the type of patient prescribed MP-AzeFlu (Dymista, a novel formulation of azelastine hydrochloride, fluticasone propionate and excipients in a single spray) in real life in the UK and physicians' reasons for prescribing it and (2) to quantify the personal and societal burden of allergic rhinitis (AR) in the UK prior to MP-AzeFlu prescription. DESIGN, SETTING AND PARTICIPANTS: This multicentre, non-interventional study enrolled patients (n=193) with moderate-to-severe AR and acute symptoms who were eligible to receive treatment with MP-AzeFlu according to its licensed indications. Information was gathered on patient demographics, AR history and symptom severity, symptomatology and AR treatments in the previous calendar year (prior to MP-AzeFlu prescription). Physicians also recorded the number of previous AR visits, specific reasons for these visits and their reason for prescribing MP-AzeFlu. RESULTS: Most patients had seasonal AR either alone (10.4%) or in combination with perennial AR (35.2%), but many had AR of unknown origin (35.8%). Prior to MP-AzeFlu prescription, patients reported troublesome symptoms (78.2%) and sleep disturbance (64.8%), with congestion considered the most bothersome (54.4%) and ocular symptoms reported by 68.4% of patients. The most frequent reason for MP-AzeFlu prescription was that other therapies were not sufficient in the past (78.8%) or not sufficient to treat acute symptoms (16.1%). 79.3% of patients reported using ≥2 AR therapies in the past year. An average of 1.6 (SD 1.9) doctor visits due to AR were reported prior to MP-AzeFlu prescription. CONCLUSIONS: In the UK, MP-AzeFlu was prescribed for individuals (≥12 years) with moderate/severe AR irrespective of (1) previous AR treatment (mono or multiple), (2) previous or likely treatment failure, (3) phenotype, (4) number of previous physician visits for AR and (5) for the relief of both acute symptoms and in anticipation of allergen exposure. SN - 2044-6055 UR - https://www.unboundmedicine.com/medline/citation/28442578/Multicentre_non_interventional_study_to_assess_the_profile_of_patients_with_uncontrolled_rhinitis_prescribed_a_novel_formulation_of_azelastine_hydrochloride_and_fluticasone_propionate_in_a_single_spray_in_routine_clinical_practice_in_the_UK_ L2 - http://bmjopen.bmj.com/cgi/pmidlookup?view=long&pmid=28442578 DB - PRIME DP - Unbound Medicine ER -